MannKind adds Furoscix heart-failure drug via $325M debt-funded acquisition, warns United Therapeutics may deprioritize key royalty product
Filed May 6, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~2 min read
5 material changes detected in this filing.
Create a free account to read the full summary — it takes 30 seconds.
Partner
Trade MNKD commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 2, 2026 2:35 AM